Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Editorial] A new vaccine for typhoid control

Last week, WHO announced prequalification of the first conjugate vaccine to prevent typhoid (Typbar TCV, manufactured by Bharat Biotech, India) after the publication of randomised controlled trials, including that by Celina Jin and colleagues in The Lancet on Sept 28, 2017. WHO has decided that Typbar TCV was successfully assessed for quality, safety, and efficacy, and it is now approved for distribution by UN agencies. Already in use in India and Nepal in babies older than 6 months, the vaccine is to be licensed for use in infants younger than 2 years.

email